A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

ClinicalTrials.gov ID: NCT03898791

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03898791. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Study identification

NCT ID: NCT03898791
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 48 participants

Conditions and interventions

Conditions

Small Cell Lung Cancer

Interventions

LY3295668 Erbumine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 16, 2019 (Actual)
Primary completion: Jun 2, 2020 (Actual)
Completion: Mar 30, 2021 (Actual)
Last update posted: Aug 5, 2021

2019 – 2021

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Highlands Oncology Group	Fayetteville	Arkansas	72703	—
Rocky Mountain Cancer Center	Denver	Colorado	80218	—
H Lee Moffitt Cancer Center	Tampa	Florida	33612	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Washington University Medical School	St Louis	Missouri	63110	—
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03756-0001	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Levine Cancer Institute- Carolinas Medical Center	Charlotte	North Carolina	28204	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	—
Prisma Health Cancer Institute	Greenville	South Carolina	29605	—
Texas Oncology Cancer Center	Austin	Texas	78705	—
Texas Oncology Fort Worth	Fort Worth	Texas	76104	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
US Oncology	The Woodlands	Texas	77380	—
Tyler Cancer Center	Tyler	Texas	75702	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03898791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 5, 2021 · Synced Nov 14, 2026